Center for Ophthalmology, Eberhard-Karls University Tuebingen, Tuebingen, Germany,
Graefes Arch Clin Exp Ophthalmol. 2014 Jan;252(1):117-24. doi: 10.1007/s00417-013-2535-9. Epub 2013 Nov 28.
To assess the short-term and long-term efficacy of oral therapy with valganciclovir in patients with Posner-Schlossman Syndrome (PSS).
This is a retrospective observational study on 11 patients with PSS treated with valganciclovir. The PSS was diagnosed clinically on the basis of recurrent episodes of anterior uveitis associated with attacks of elevated intraocular pressure (IOP). All patients who did not respond to aciclovir, or whose cytomegalovirus (CMV) DNA polymerase chain reaction (PCR) analysis of the aqueous humour was positive, were treated with valganciclovir (Valcyte®). Initially, the drug was given 900 mg twice daily for 3 weeks, followed by 450 mg twice daily for a mean period of 20 months (range 10-46 months).
Eleven patients with mean age of 44 years were included in this study. Four of 11 patients were working in a sanitary profession. Before initiation of valgancicloivir therapy, the highest IOP was 68 mmHg (mean 45 mmHg ±9 mmHg). In the first week of treatment, the IOP decreased significantly (mean 16 mmHg ±10 mmHg) and maintained stability during the entire treatment period. In seven of 11 (63.6 %) patients, valganciclovir led to resolution of inflammatory activity and stable IOP. In six patients, the therapy could be discontinued after a mean of 14 months. However, two patients had a recurrence after discontinuation of valganciclovir treatment. No side effects of therapy were observed.
Long-term oral therapy with valganciclovir seems to lower the recurrence rate in patients with clinically diagnosed PSS.
评估口服缬更昔洛韦治疗 Posner-Schlossman 综合征（PSS）患者的短期和长期疗效。
这是一项回顾性观察研究，共纳入 11 例接受缬更昔洛韦治疗的 PSS 患者。根据复发性前葡萄膜炎伴眼压升高（IOP）发作的临床诊断 PSS。所有对阿昔洛韦无反应或眼房水中巨细胞病毒（CMV）DNA 聚合酶链反应（PCR）分析阳性的患者均接受缬更昔洛韦（Valcyte®）治疗。最初，患者每日两次给予 900mg 缬更昔洛韦，持续 3 周，然后每日两次给予 450mg，平均治疗 20 个月（范围 10-46 个月）。
本研究共纳入 11 例平均年龄为 44 岁的患者。11 例患者中有 4 例从事卫生职业。在开始缬更昔洛韦治疗前，最高眼压为 68mmHg（平均 45mmHg±9mmHg）。在治疗的第一周，眼压显著下降（平均 16mmHg±10mmHg），并在整个治疗期间保持稳定。11 例患者中的 7 例（63.6%），缬更昔洛韦导致炎症活动和稳定的眼压。6 例患者在平均 14 个月后停止治疗。然而，2 例患者在缬更昔洛韦治疗停药后复发。未观察到治疗的副作用。
长期口服缬更昔洛韦似乎降低了临床诊断为 PSS 患者的复发率。
